Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702

A Placebo-controlled, Single-blind, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Drug Interaction of GSK1034702 After Repeat Doses in Healthy Subjects

GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potential to investigate repeated doses of the study medicine. The study will investigate the following questions, do repeated doses of the study medicine have any important side effects when taken by mouth? How much of the study medicine gets into the bloodstream, and how quickly does the body get rid of it? Does the study medicine affect memory, attention and problem-solving skills? What are the effects when the study medicine and dextromethorphan are taken together.

Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.

Inclusion Criteria: Male or female of non childbearing potential Generally healthy Body mass index 19 - 29.9 kg/m2 (inclusive), body weight greater than or equal to 50 kg for males and greater than of equal to 45 kg for females Normal Laboratory test results Exclusion Criteria: Abuse of drugs or alcohol Smoker or history of regular use of tobacco- or nicotine-containing products in the past 6 months ECG abnormality (personal or family history) Psychiatric disorder Asthma or a history of asthma Medical illness

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.